Cargando…
The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
OBJECTIVES: We examined the effect of Revacept, an Fc fusion protein which is specifically linked to the extracellular domain of glycoprotein VI (GPVI), on thrombus formation after vessel wall injury and on experimental stroke in mice. BACKGROUND: Several antiplatelet drugs for the treatment of myoc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720811/ https://www.ncbi.nlm.nih.gov/pubmed/23935828 http://dx.doi.org/10.1371/journal.pone.0066960 |
_version_ | 1782277994305290240 |
---|---|
author | Goebel, Silvia Li, Zhongmin Vogelmann, Jasmin Holthoff, Hans-Peter Degen, Heidrun Hermann, Dirk M. Gawaz, Meinrad Ungerer, Martin Münch, Götz |
author_facet | Goebel, Silvia Li, Zhongmin Vogelmann, Jasmin Holthoff, Hans-Peter Degen, Heidrun Hermann, Dirk M. Gawaz, Meinrad Ungerer, Martin Münch, Götz |
author_sort | Goebel, Silvia |
collection | PubMed |
description | OBJECTIVES: We examined the effect of Revacept, an Fc fusion protein which is specifically linked to the extracellular domain of glycoprotein VI (GPVI), on thrombus formation after vessel wall injury and on experimental stroke in mice. BACKGROUND: Several antiplatelet drugs for the treatment of myocardial infarction or ischemic stroke with potent anti-ischemic effects have been developed, but all incur a significant risk of bleeding. METHODS: Platelet adhesion and thrombus formation after endothelial injury was monitored in the carotid artery by intra-vital fluorescence microscopy. The morphological and clinical consequences of stroke were investigated in a mouse model with a one hour-occlusion of the middle cerebral artery. RESULTS: Thrombus formation was significantly decreased after endothelial injury by 1 mg/kg Revacept IV, compared to Fc only. 1 mg/kg Revacept IV applied in mice with ischemic stroke immediately before reperfusion significantly improved functional outcome, cerebral infarct size and edema compared to Fc only. Also treatment with 10 mg/kg rtPA was effective, and functional outcome was similar in both treatment groups. The combination of Revacept with rtPA leads to increased reperfusion compared to treatment with either agent alone. In contrast to rtPA, however, there were no signs of increased intracranial bleeding with Revacept. Both rtPA and Revacept improved survival after stroke compared to placebo treatment. Revacept and vWF bind to collagen and Revacept competitively prevented the binding of vWF to collagen. CONCLUSIONS: Revacept reduces arterial thrombus formation, reduces cerebral infarct size and edema after ischemic stroke, improves functional and prognostic outcome without intracranial bleeding. Revacept not only prevents GPVI-mediated, but probably also vWF-mediated platelet adhesion and aggregate formation. Therefore Revacept might be a potent and safe tool to treat ischemic complications of stroke. |
format | Online Article Text |
id | pubmed-3720811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37208112013-08-09 The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke Goebel, Silvia Li, Zhongmin Vogelmann, Jasmin Holthoff, Hans-Peter Degen, Heidrun Hermann, Dirk M. Gawaz, Meinrad Ungerer, Martin Münch, Götz PLoS One Research Article OBJECTIVES: We examined the effect of Revacept, an Fc fusion protein which is specifically linked to the extracellular domain of glycoprotein VI (GPVI), on thrombus formation after vessel wall injury and on experimental stroke in mice. BACKGROUND: Several antiplatelet drugs for the treatment of myocardial infarction or ischemic stroke with potent anti-ischemic effects have been developed, but all incur a significant risk of bleeding. METHODS: Platelet adhesion and thrombus formation after endothelial injury was monitored in the carotid artery by intra-vital fluorescence microscopy. The morphological and clinical consequences of stroke were investigated in a mouse model with a one hour-occlusion of the middle cerebral artery. RESULTS: Thrombus formation was significantly decreased after endothelial injury by 1 mg/kg Revacept IV, compared to Fc only. 1 mg/kg Revacept IV applied in mice with ischemic stroke immediately before reperfusion significantly improved functional outcome, cerebral infarct size and edema compared to Fc only. Also treatment with 10 mg/kg rtPA was effective, and functional outcome was similar in both treatment groups. The combination of Revacept with rtPA leads to increased reperfusion compared to treatment with either agent alone. In contrast to rtPA, however, there were no signs of increased intracranial bleeding with Revacept. Both rtPA and Revacept improved survival after stroke compared to placebo treatment. Revacept and vWF bind to collagen and Revacept competitively prevented the binding of vWF to collagen. CONCLUSIONS: Revacept reduces arterial thrombus formation, reduces cerebral infarct size and edema after ischemic stroke, improves functional and prognostic outcome without intracranial bleeding. Revacept not only prevents GPVI-mediated, but probably also vWF-mediated platelet adhesion and aggregate formation. Therefore Revacept might be a potent and safe tool to treat ischemic complications of stroke. Public Library of Science 2013-07-23 /pmc/articles/PMC3720811/ /pubmed/23935828 http://dx.doi.org/10.1371/journal.pone.0066960 Text en © 2013 Goebel et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Goebel, Silvia Li, Zhongmin Vogelmann, Jasmin Holthoff, Hans-Peter Degen, Heidrun Hermann, Dirk M. Gawaz, Meinrad Ungerer, Martin Münch, Götz The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke |
title | The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke |
title_full | The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke |
title_fullStr | The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke |
title_full_unstemmed | The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke |
title_short | The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke |
title_sort | gpvi-fc fusion protein revacept improves cerebral infarct volume and functional outcome in stroke |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720811/ https://www.ncbi.nlm.nih.gov/pubmed/23935828 http://dx.doi.org/10.1371/journal.pone.0066960 |
work_keys_str_mv | AT goebelsilvia thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT lizhongmin thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT vogelmannjasmin thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT holthoffhanspeter thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT degenheidrun thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT hermanndirkm thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT gawazmeinrad thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT ungerermartin thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT munchgotz thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT goebelsilvia gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT lizhongmin gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT vogelmannjasmin gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT holthoffhanspeter gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT degenheidrun gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT hermanndirkm gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT gawazmeinrad gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT ungerermartin gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke AT munchgotz gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke |